Colgate Explores Divestiture of Legacy Personal Care Brands as Shares Trade Above Intrinsic Value

What happened

Colgate-Palmolive is reportedly working with Goldman Sachs to sell Softsoap, Irish Spring, and Speed Stick, but conventional strategic buyers face hurdles, leaving the divestiture path uncertain. The potential sale would sharpen focus on higher-growth oral care and pet nutrition, aligning with management’s stated priority on science-led innovation and faster-growing markets. However, the current valuation already prices in much of that strategic upside, with shares at $76.98 versus a base-case DCF of $65.46 and a negative margin of safety. Q2 2025 results showed only 1% sales growth and flat volume, with North America operating profit down 9% on input costs, underscoring near-term execution challenges. While the brand portfolio rationalization could improve long-term mix, the immediate impact on earnings and cash flows is likely muted, reinforcing the existing HOLD rating.

Implication

The divestiture could unlock modest value if proceeds are redeployed into buybacks or higher-growth categories, but likely buyers are scarce and the brands are mature with limited pricing power. Given CL trades at a ~18% premium to DCF and organic growth is sluggish with North American margin pressure, the risk/reward remains unattractive for new capital. Until the sale materializes and financial impact is quantified, the stock may remain range-bound, with any upside dependent on improving volume trends or margin recovery. A share buyback using sale proceeds could be accretive but may not offset ongoing FX and emerging market volatility. Overall, maintain a cautious stance and only consider adding on meaningful pullbacks toward the mid-$60s.

Thesis delta

The potential divestiture of Softsoap, Irish Spring, and Speed Stick is consistent with a portfolio rationalization strategy but does not alter Colgate’s core moat in oral care or pet nutrition. The HOLD rating is maintained because the valuation already embeds optimistic strategic outcomes, and the sale's uncertain execution and limited impact on near-term growth leave the risk/reward unchanged. Only a completed transaction with clear value creation or a pullback toward the DCF value would warrant revisiting the thesis.